Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Discovery of a novel and potent class of anti-HIV-1 maturation inhibitors with improved virology profile against gag polymorphisms.

Tang J, Jones SA, Jeffrey JL, Miranda SR, Galardi CM, Irlbeck DM, Brown KW, McDanal CB, Johns BA.

Bioorg Med Chem Lett. 2017 Jun 15;27(12):2689-2694. doi: 10.1016/j.bmcl.2017.04.042. Epub 2017 Apr 20.

PMID:
28454672
2.

Synthesis and Biological Evaluation of Macrocyclized Betulin Derivatives as a Novel Class of Anti-HIV-1 Maturation Inhibitors.

Tang J, Jones SA, Jeffery JL, Miranda SR, Galardi CM, Irlbeck DM, Brown KW, McDanal CB, Han N, Gao D, Wu Y, Shen B, Liu C, Xi C, Yang H, Li R, Yu Y, Sun Y, Jin Z, Wang E, Johns BA.

Open Med Chem J. 2014 Sep 3;8:23-7. doi: 10.2174/1874104501408010023. eCollection 2014.

3.

No association found between the detection of either xenotropic murine leukemia virus-related virus or polytropic murine leukemia virus and chronic fatigue syndrome in a blinded, multi-site, prospective study by the establishment and use of the SolveCFS BioBank.

Irlbeck DM, Vernon SD, McCleary KK, Bateman L, Klimas NG, Lapp CW, Peterson DL, Brown JR, Remlinger KS, Wilfret DA, Gerondelis P.

BMC Res Notes. 2014 Aug 4;7:461. doi: 10.1186/1756-0500-7-461.

4.

Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity.

Henderson GJ, Lee SK, Irlbeck DM, Harris J, Kline M, Pollom E, Parkin N, Swanstrom R.

Antimicrob Agents Chemother. 2012 Feb;56(2):623-33. doi: 10.1128/AAC.05549-11. Epub 2011 Nov 14.

5.

Virologic failure in therapy-naive subjects on aplaviroc plus lopinavir-ritonavir: detection of aplaviroc resistance requires clonal analysis of envelope.

Kitrinos KM, Amrine-Madsen H, Irlbeck DM, Word JM, Demarest JF; CCR100136 Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1124-31. doi: 10.1128/AAC.01057-08. Epub 2008 Dec 15.

6.

Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.

Demarest JF, Amrine-Madsen H, Irlbeck DM, Kitrinos KM; CCR102881 Clinical Study Team.

Antimicrob Agents Chemother. 2009 Mar;53(3):1116-23. doi: 10.1128/AAC.01055-08. Epub 2008 Dec 15.

7.

Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.

Underwood MR, Ross LL, Irlbeck DM, Gerondelis P, Rouse E, St Clair MH, Trinh L, Parkin N, Lanier E.

J Infect Dis. 2009 Jan 1;199(1):84-8. doi: 10.1086/595296.

PMID:
19032103
8.

Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.

Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF.

AIDS. 2008 Jul 31;22(12):1425-31. doi: 10.1097/QAD.0b013e32830184ba.

PMID:
18614865
9.

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Davis NL, Caley IJ, Brown KW, Betts MR, Irlbeck DM, McGrath KM, Connell MJ, Montefiori DC, Frelinger JA, Swanstrom R, Johnson PR, Johnston RE.

J Virol. 2000 Jan;74(1):371-8. Erratum in: J Virol 2000 Apr;74(7):3430.

10.

Supplemental Content

Loading ...
Support Center